Haptoglobin polymorphism and peripheral arterial occlusive disease

被引:62
作者
Delanghe, J
Langlois, M
Duprez, D
De Buyzere, M
Clement, D
机构
[1] State Univ Ghent Hosp, Dept Clin Chem, B-9000 Ghent, Belgium
[2] Belgian Natl Fund Sci Res, Flanders, Belgium
[3] State Univ Ghent Hosp, Dept Cardiol, B-9000 Ghent, Belgium
关键词
peripheral arterial occlusive disease; atherosclerosis; haptoglobin polymorphism; treadmill testing; angiogenesis;
D O I
10.1016/S0021-9150(99)00079-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Haptoglobin (Hp) 2-2 phenotype is a genetic risk factor in coronary atherosclerosis. In this study, haptoglobin phenotypes were determined in 141 patients with peripheral arterial occlusive disease (PAOD) and compared to a reference population (n = 1000). The relative Hpl allele frequency was decreased among PAOD patients (0.294 vs. 0.403 for the reference population, P < 0.01) due to an overrepresentation of the Hp 2-2 phenotype (50%, odds ratio 1.82(95% C.I. 1.28-2.60), P < 0.001). This finding was even more pronounced in non-diabetic and in non-smoking PAOD patients (Hpl allele frequencies: 0.265 and 0.228, respectively). Serum lipids, inflammatory parameters, and blood pressure levels were comparable among the Hp phenotypes, but serum levels of the antioxidant vitamin C were lower in Hp 2-2 patients than in patients with another phenotype (P < 0.05). In PAOD patients with severe atherosclerotic lesions, maximal walking distance of patients carrying a Hp 2-2 phenotype (225-525 m) exceeded that of other Hp phenotypes (50-242 m) (interquartile ranges) (P < 0.05). The findings demonstrate that, despite an increased risk for developing PAOD, the Hp 2-2 phenotype is associated with a longer maximal walking distance which might be attributed to the earlier reported in vitro angiogenic properties of the Hp 2-2 molecule. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:287 / 292
页数:6
相关论文
共 30 条
[1]  
ALLAIN CC, 1974, CLIN CHEM, V20, P470
[2]   COVARIATION BETWEEN WALKING ABILITY AND CIRCULATORY ALTERATIONS IN PATIENTS WITH INTERMITTENT CLAUDICATION [J].
ARFVIDSSON, B ;
WENNMALM, A ;
GELIN, J ;
DAHLLOF, AG ;
HALLGREN, B ;
LUNDHOLM, K .
EUROPEAN JOURNAL OF VASCULAR SURGERY, 1992, 6 (06) :642-646
[3]  
BEUTLER HO, 1984, METHOD ENZYMAT AN, V6, P376
[4]  
BUCOLO G, 1973, CLIN CHEM, V19, P476
[5]   EFFECT OF THE HAPTOGLOBIN PHENOTYPE ON THE SIZE OF A MYOCARDIAL INFARCT [J].
CHAPELLE, JP ;
ALBERT, A ;
SMEETS, JP ;
HEUSGHEM, C ;
KULBERTUS, HE .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (08) :457-463
[6]   IDENTIFICATION OF HAPTOGLOBIN AS AN ANGIOGENIC FACTOR IN SERA FROM PATIENTS WITH SYSTEMIC VASCULITIS [J].
CID, MC ;
GRANT, DS ;
HOFFMAN, GS ;
AUERBACH, R ;
FAUCI, AS ;
KLEINMAN, HK .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (03) :977-985
[7]   COMPARATIVE DIAGNOSTIC-VALUE OF ANKLE-TO-BRACHIAL INDEX AND TRANSCUTANEOUS OXYGEN-TENSION AT REST AND AFTER EXERCISE IN PATIENTS WITH INTERMITTENT CLAUDICATION [J].
DEGROOTE, P ;
MILLAIRE, A ;
DEKLUNDER, G ;
MARACHE, P ;
DECOULX, E ;
DUCLOUX, G .
ANGIOLOGY, 1995, 46 (02) :115-122
[8]   Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery [J].
Delanghe, J ;
Cambier, B ;
Langlois, M ;
DeBuyzere, M ;
Neels, H ;
DeBacquer, D ;
VanCauwelaert, P .
ATHEROSCLEROSIS, 1997, 132 (02) :215-219
[9]  
DELANGHE J, 1995, J CARDIOVASC RISK, V2, P323
[10]   HAPTOGLOBIN POLYMORPHISM AND COMPLICATIONS IN ESTABLISHED ESSENTIAL ARTERIAL-HYPERTENSION [J].
DELANGHE, JR ;
DUPREZ, DA ;
DEBUYZERE, ML ;
BERGEZ, BM ;
CALLENS, BY ;
LEROUXROELS, GG ;
CLEMENT, DL .
JOURNAL OF HYPERTENSION, 1993, 11 (08) :861-867